Decent Organic Sales Growth Expected for Abbott Laboratories (ABT) in 2026

Group 1 - Abbott Laboratories (NYSE:ABT) is recognized as one of the top 12 Medical Devices stocks favored by Hedge Funds [1] - Larry Biegelsen from Wells Fargo maintained an Overweight rating on Abbott Laboratories but reduced the target price from $146 to $122, indicating a 15% upside potential from the current stock level [1] - Joanne Wuensch from Citi also reiterated a Buy rating for Abbott Laboratories, lowering the target price from $155 to $140, emphasizing the need for improved results for the stock to regain momentum [3] Group 2 - Abbott Laboratories operates in the healthcare sector, focusing on discovering, developing, and marketing healthcare products globally, with four main segments: Diagnostic Products, Established Pharmaceutical Products, Medical Devices, and Nutritional Products [4] - The company faced transitory headwinds that led to missing consensus sales estimates for the fourth quarter, with management projecting 6.5%-7.5% organic sales growth for 2026, which is below prior consensus [2]